FR3100452B1 - Méthode de diagnostic de peaux agées - Google Patents

Méthode de diagnostic de peaux agées Download PDF

Info

Publication number
FR3100452B1
FR3100452B1 FR1909769A FR1909769A FR3100452B1 FR 3100452 B1 FR3100452 B1 FR 3100452B1 FR 1909769 A FR1909769 A FR 1909769A FR 1909769 A FR1909769 A FR 1909769A FR 3100452 B1 FR3100452 B1 FR 3100452B1
Authority
FR
France
Prior art keywords
diagnosis method
aging skin
glycan
skin diagnosis
mannose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1909769A
Other languages
English (en)
Other versions
FR3100452A1 (fr
Inventor
Mark Donovan
Dominique Bernard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Priority to FR1909769A priority Critical patent/FR3100452B1/fr
Priority to PCT/EP2020/074604 priority patent/WO2021043906A1/fr
Publication of FR3100452A1 publication Critical patent/FR3100452A1/fr
Application granted granted Critical
Publication of FR3100452B1 publication Critical patent/FR3100452B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/148—Screening for cosmetic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

Méthode de diagnostic de peaux agées La présente invention concerne une méthode de diagnostic d’une peau âgée chez un sujet, comprenant une étape (a) de mesure, dans un échantillon de peau du sujet, du niveau d’au moins un N-glycane choisi dans le groupe constitué du glycane de type riche en mannose M7, du glycane de type riche en mannose M8, du glycane de type riche en mannose M9, du glycane de type complexe F(6)A2G(4)2S1 et du glycane de type complexe A2G1GalNAc1. Figure pour l'abrégé : néant
FR1909769A 2019-09-05 2019-09-05 Méthode de diagnostic de peaux agées Active FR3100452B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1909769A FR3100452B1 (fr) 2019-09-05 2019-09-05 Méthode de diagnostic de peaux agées
PCT/EP2020/074604 WO2021043906A1 (fr) 2019-09-05 2020-09-03 Méthode pour le diagnostic d'une peau âgée

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1909769 2019-09-05
FR1909769A FR3100452B1 (fr) 2019-09-05 2019-09-05 Méthode de diagnostic de peaux agées

Publications (2)

Publication Number Publication Date
FR3100452A1 FR3100452A1 (fr) 2021-03-12
FR3100452B1 true FR3100452B1 (fr) 2021-09-17

Family

ID=68733359

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1909769A Active FR3100452B1 (fr) 2019-09-05 2019-09-05 Méthode de diagnostic de peaux agées

Country Status (2)

Country Link
FR (1) FR3100452B1 (fr)
WO (1) WO2021043906A1 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2811862B1 (fr) 2000-07-19 2004-09-17 Joubert Productions Cloture electrique
FR2825277B1 (fr) 2001-05-30 2004-10-15 Oreal Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd
FR2864785B1 (fr) 2004-01-06 2006-02-10 Oreal Composition cosmetique comprenant un extrait de feuille d'olivier et un extrait d'eau de vegetation des olives
FR2946347B1 (fr) 2009-06-04 2013-01-04 Oreal Agents anti-age et compositions les contenant
WO2012038929A1 (fr) * 2010-09-24 2012-03-29 L'oreal Utilisation cosmetique de la dermcidine, analogues ou fragments de celle-ci
FR2965357B1 (fr) * 2010-09-24 2014-10-03 Oreal Utilisation cosmetique de la dermcidine, analogues ou fragments de celle-ci
FR2991167B1 (fr) 2012-06-01 2014-09-05 Oreal Utilisation cosmetique d'un extrait de laminaria ochroleuca et d'un extrait d'aphanizomenon flos-aquae pour lutter contre les signes du vieillissement cutane
FR2994528B1 (fr) 2012-08-20 2014-11-28 Oreal Utilisation cosmetique de l'huile essentielle de laserpitium siler l. contre les signes cutanes du vieillissement.
FR3007650A1 (fr) 2013-06-28 2015-01-02 Oreal Utilisation cosmetique et/ou dermatologique, d'un lysat de bacteries du genre vitreoscilla sp., notamment de l'espece vitreoscilla filiformis dans un milieu de fermentation complet, pour prevenir et/ou traiter le vieillissement cutane.
FR3027797B1 (fr) 2014-10-30 2020-07-10 L'oreal Utilisation de derives d'acide salicylique lipophiles
FR3070494B1 (fr) * 2017-08-23 2022-07-01 Oreal Methode de diagnostic d'une peau presentant des signes de vieillissement

Also Published As

Publication number Publication date
WO2021043906A1 (fr) 2021-03-11
FR3100452A1 (fr) 2021-03-12

Similar Documents

Publication Publication Date Title
Cox et al. Associations between vascular risk factors and brain MRI indices in UK Biobank
Brickman Contemplating Alzheimer’s disease and the contribution of white matter hyperintensities
Montine et al. Increased cerebrospinal fluid F 2-isoprostanes are associated with aging and latent Alzheimer’s disease as identified by biomarkers
EP2322531A3 (fr) Méthodes permettant de diagnostiquer la démence et autres troubles neurologiques
CN108903942B (zh) 一种利用复数fMRI空间源相位识别空间差异的方法
Grand'Maison et al. Early cortical thickness changes predict β-amyloid deposition in a mouse model of Alzheimer's disease
WO2021067850A3 (fr) Méthodes de détection d'arncirc
Van Schependom et al. The effect of morphological and microstructural integrity of the corpus callosum on cognition, fatigue and depression in mildly disabled MS patients
EP2557421A3 (fr) Activité mitochondriale altérée dans les maladies liées au stress oxydant
FR3100452B1 (fr) Méthode de diagnostic de peaux agées
Hong et al. A convergent structure–function substrate of cognitive imbalances in autism
MX2022000444A (es) Un biomarcador para la enfermedad de alzheimer utilizando muestras de sangre de sujetos con diagnostico clinico de la enfermedad de alzheimer.
FR3100451B1 (fr) Méthode de diagnostic de peaux sèches
Vuksanovic et al. Development of a brief measure of generativity and ego-integrity for use in palliative care settings
WO2020213969A3 (fr) Biomarqueur pour diagnostiquer un dysfonctionnement des cellules endothéliales cornéennes
RU2003138027A (ru) Способ диагностики поструальных нарушений у пациентов с органической патологией головного мозга
Ecarnot et al. Epidemiology of Sarcopenia
FR3097558B1 (fr) Méthode de diagnostic d’un vieillissement prématuré de la peau
KR20180118948A (ko) 대각선 귓불주름을 이용한 퇴행성 뇌질환 진단 방법
FR3091351B1 (fr) Biomarqueur de la maladie de fabry
CN108960051A (zh) 一种基于频率分析的自适应csi信号辅助滤波方法
RU2019133312A (ru) Способ ранней доклинической диагностики болезни Паркинсона по концентрации катехоламинов в слезной жидкости пациента
WO2019234677A3 (fr) Biomarqueurs pour un diagnostic précoce non invasif de maladies infectieuses
UA117525C2 (uk) Спосіб діагностики розвитку тяжкої прееклампсії
Brussel et al. The effect of morphological and microstructural integrity of the corpus callosum on cognition, fatigue and depression in mildly disabled MS patients.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210312

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5